Entasis Therapeutics Holdings Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was USD 0 compared to USD 7.000 million a year ago. Operating loss was USD 12.600 million compared to USD 4.127 million a year ago. Net loss was USD 11.133 million compared to USD 3.485 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.27 a year ago. For the nine months, sales was USD 0 compared to USD 7.000 million a year ago. Operating loss was USD 41.484 million compared to USD 32.416 million a year ago. Net loss was USD 39.795 million compared to USD 29.808 million a year ago. Basic loss per share from continuing operations was USD 1.97 compared to USD 2.27 a year ago.